SCHEMBL29214944

SCHEMBL29214944

CCOc1ccc(-c2cncc(C(=O)NN=Cc3ccc(OC)cc3)n2)cc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.57
▸ MEN1 O00255 2/20 0.57
▸ SCN2A Q99250 3/20 0.57
▸ SCN10A Q9Y5Y9 3/20 0.57
▸ ALDH1A1 P00352 6/20 0.53
▸ MAPT P10636 5/20 0.53
▸ SMN1; SMN2 Q16637 5/20 0.53
▸ HPGD P15428 4/20 0.53
▸ KDM4E B2RXH2 3/20 0.53
▸ HTT P42858 1/20 0.53
▸ RAB9A P51151 3/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ TP53 P04637 2/20 0.53
▸ LMNA P02545 1/20 0.49
▸ AMY1A P0DUB6 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ IDO1 P14902 1/20 0.48
▸ PKM P14618 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24993519 1.00 KMT2A (0.57) KMT2AMEN1SCN2ASCN10AALDH1A1
SCHEMBL29214915 0.92 SCN2A (0.55) KMT2AMEN1SCN2ASCN10AALDH1A1
SCHEMBL30925931 0.92 SCN2A (0.57) KMT2AMEN1SCN2ASCN10AALDH1A1
SCHEMBL24993618 0.92 SCN2A (0.55) KMT2AMEN1SCN2ASCN10AALDH1A1
SCHEMBL29215186 0.92 SCN2A (0.57) KMT2AMEN1SCN2ASCN10AALDH1A1
SCHEMBL29215180 0.92 SCN2A (0.57) KMT2AMEN1SCN2ASCN10AALDH1A1
SCHEMBL29214918 0.91 SCN2A (0.56) KMT2AMEN1SCN2ASCN10AALDH1A1
SCHEMBL24994757 0.91 SCN2A (0.56) KMT2AMEN1SCN2ASCN10AALDH1A1
SCHEMBL24993515 0.91 SCN2A (0.58) KMT2AMEN1SCN2ASCN10AALDH1A1
SCHEMBL30925977 0.91 RAB9A (0.61) KMT2AMEN1SCN2ASCN10AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240335442-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS UNIVERSIDADE FEDERAL DO RIO DE JANEIRO – UFRJ (BR) 2024-10-10 — — US claimed
CN-118076348-A N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same 欧罗法玛实验室股份公司 2024-05-24 — — CN claimed
US-20240335442-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS UNIVERSIDADE FEDERAL DO RIO DE JANEIRO – UFRJ (BR) 2024-10-10 — — US disclosed
CN-118076348-A N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same 欧罗法玛实验室股份公司 2024-05-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335442-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS SCN1A, SCN7A, SCN8A KMT2A 1963/4885MEN1 2491/4885SCN2A 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback